Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 22, 2022
A review decision by the European Medicines Agency (EMA) is expected in the second half of 2023 If approved, sparsentan will be a first-in-class treatment to address the significant unmet medical...
-
Aug 22, 2022
U.S. District Court for the District of Delaware rules Teva Pharmaceuticals infringes VFMCRP patent Disputes with all other Abbreviated New Drug Application (ANDA) filers regarding Velphoro® have...
-
Aug 19, 2022
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy...
-
Aug 18, 2022
With this recommendation, eligible patients in England, Wales and Northern Ireland will be able to access the first orally administered therapy for GPA/MPA, two main forms of ANCA-associated...
-
Aug 2, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR All regulatory clearances received for the acquisition of Vifor Pharma AG Settlement of the offer is scheduled for 9 August 2022 Seasoned biopharma...
-
Jul 13, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia, and St. Gallen, Switzerland, 13 July 2022 – CSL Limited (ASX: CSL; USOTC:CSLLY) today announced an update regarding the Vifor...
-
May 12, 2022
St. Gallen, Switzerland, 12 May 2022 – CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to...
-
Apr 28, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches in Europe...
-
Apr 26, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Dividend of CHF 2.00 approved All Board members re-elected...
-
Apr 4, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Full data set supports long-term use of Veltassa® (patiromer) to control potassium buildup (hyperkalemia) in heart failure patients while on...